Video: what does a new ruling on Canada’s equivalent to patent term extension mean for the pharmaceutical industry?

Last week, we wrote about the Federal Court’s latest judicial review which sheds light on how courts may view eligibility of patents for Canada’s recently introduced Certificates of Supplementary Protection (CSPs). What can pharmaceutical industry players take away from this review?

Our intellectual property team shares their informal, work-from-home conversation on what the ruling means, including discussion of:

• what pharmaceutical companies will need to consider when applying for CSPs in light of the Federal Court’s decision;
• how courts may interpret the role of Canada’s obligations under international treaties in the context of patent protection; and
• what outcome we can expect once the Minister of Health Canada is finished their redetermination.

Play the video below for our IP team’s commentary on this evolving issue.

To discuss these issues, please contact the author(s).

This publication is a general discussion of certain legal and related developments and should not be relied upon as legal advice. If you require legal advice, we would be pleased to discuss the issues in this publication with you, in the context of your particular circumstances.

For permission to republish this or any other publication, contact Janelle Weed.

© 2024 by Torys LLP.

All rights reserved.